A post hoc analysis of the DIAMOND trial evaluating CGM use in adults with both type 1 and type 2 diabetes on intensive insulin therapy reported the greatest HbA1c improvement in those with an initial HbA1c value ≥9%.16 Similar findings were observed among participants with lower baseline TIR.17 Our results are consistent with and expand these findings to patients with type 2 diabetes on less intensive insulin therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.